KENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announced that it has received total proceeds of $8,824,710 from the exercise of warrants to purchase 823,530 shares of the common stock of the Company, par value $0.0001 per share ("common stock"), at an exercise price of $6.83, and warrants to purchase 800,000 shares of commons stock, at an exercise price of $4.00, respectively. The warrants were issued pursuant to private placements that closed

Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform          For the first time, Firefly also unveils a new strategic initiative to build the world's first foundation model of the human brain using its BNA™ technology KENMORE, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its acceptance into the NVIDIA Connect program. Firefly expects to use the powerful new tools and reso

- University of Waterloo's Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon - KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to congratulate Christopher Wilson, PhD, on being recognized by the University of Waterloo's ("UW") Faculty of Enginee

3/A - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

EFFECT - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024. "I look forward to taking on a more active leadership role as Executive Chairman," said Greg Lipschitz, newly appointed Executive Chairman of Firefly. "I believe that Firefly is uniquely positioned at the intersection of artificial intelligence and brain health that I have l

TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life

Company successfully listed on Nasdaq under the symbol "AIFF" Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering wi

SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)